🇺🇸

US SEC Filing Intelligence

· daily

US IPO Pipeline SEC S-1 Filings — May 19, 2026

The IPO pipeline on May 19, 2026, presents a highly polarized landscape, ranging from a development-stage interior design company with a going concern warning to a biotech firm with a $75M strategic investment from Regeneron. The most significant period-over-period trend is the escalating cash burn at Parabilis Medicines, where net losses widened 24% YoY to $145.9M, contrasting sharply with the nascent stage of Lawaken Group, whose CEO compensation surged 531% YoY to $1.85M despite a lack of employee benefits. A notable capital allocation pattern emerges with JAB Acquisition Corp I raising $150M in a SPAC IPO, signaling continued appetite for blank-check vehicles targeting tech, healthcare, and logistics. The absence of insider trading data across all filings is a critical gap, limiting conviction signals. The most actionable development is Regeneron's $75M private placement in Parabilis at a 10% discount to the IPO price, which provides a strong validation signal but also creates a potential overhang. The pipeline is dominated by high-risk, early-stage issuers, with 3 of 5 filings showing negative or going-concern sentiment, suggesting a cautious market reception ahead.

5 high priority 5 total filings
· daily

Global High-Priority Regulatory Events — May 19, 2026

The 50 filings from May 19, 2026, reveal a market dominated by capital return events (buybacks/dividends) and significant M&A/de-SPAC activity, but with underlying financial stress in several sectors. A clear theme is the aggressive return of capital to shareholders, with Dhanuka Agritech, Zydus Lifesciences, Welspun Living, and Sarla Performance Fibers announcing buybacks totaling over ₹1,466 crore, signaling strong balance sheets and management confidence. However, this is contrasted by severe financial distress in the US small-cap space, where Natural Alternatives International (NAII) reported a 79% gross profit collapse and TechPrecision Corp secured only a 4-month credit extension, highlighting acute liquidity pressures. The M&A landscape is active but mixed; the Einride/Legato de-SPAC is progressing with a $1.35B valuation and a June 4 vote, while the Permian Basin Royalty Trust deal remains non-binding and the Plum/Controlled Thermal merger faces delays. Insider activity is sparse but notable, with a significant 2.9M share sale by Invesco in Delhivery and a promoter pledge exceeding 50% at Damodar Industries, both bearish signals. Overall, the digest points to a bifurcated market: cash-rich companies are rewarding shareholders, while others face existential refinancing risks and operational deterioration.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 19, 2026

The 36 filings from May 19, 2026, reveal a bifurcated market where top-line growth is often masking underlying margin compression and cash flow deterioration. A clear theme is 'growth at a cost,' with companies like Cisco (12% revenue growth) and Energy Vault (156% revenue growth) showing strong sales but facing margin pressure or widening losses. Conversely, several micro-cap and pre-revenue companies (e.g., ShorePower, RMX Industries) are experiencing severe revenue declines and cash burn, signaling distress. Insider activity is notably absent from the filings, limiting conviction signals, but capital allocation patterns show a mix of aggressive reinvestment (Eagle Materials, Movano) and debt-fueled growth (Nextpower, James Hardie). The most actionable intelligence lies in identifying companies with genuine operational leverage versus those masking structural issues with one-time gains or accounting adjustments. Key sectors to watch include energy storage (Energy Vault's explosive growth vs. cash burn) and building materials (James Hardie's AZEK integration vs. Eagle Materials' margin resilience).

36 high priority 36 total filings
· daily

US SEC Trading Suspension Halt Orders — May 19, 2026

The single filing for May 19, 2026, from Bitcoin Depot Inc. (BTM) represents a catastrophic corporate event: a Chapter 11 bankruptcy filing immediately triggering a Nasdaq delisting. This is the highest materiality event possible (10/10), with the company not appealing the delisting, effectively confirming a total equity wipeout for common shareholders. The delisting is driven by both the bankruptcy (Nasdaq Rules 5101, 5110(b), IM-5101-1) and a failure to file a timely Form 10-Q (Rule 5250(c)), indicating severe operational and reporting distress. The company's own filing explicitly warns of a 'significant or complete loss' for security holders. With only one filing in the stream, the dominant theme is a single-entity, high-severity credit and equity risk event with no mitigating factors or positive trends.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 19, 2026

The 40 filings from May 19, 2026, paint a picture of a market bifurcated between aggressive capital management and acute distress. While several firms (STORE Capital, Diversified Energy, Kimbell Royalty) are successfully refinancing debt at lower rates or making accretive acquisitions, a significant cluster of companies is exhibiting classic pre-bankruptcy distress signals. Bitcoin Depot has already filed for Chapter 11 and faces delisting, while TechPrecision, Zoomcar, and Aether Holdings are executing last-resort financing or settlement agreements that signal severe liquidity constraints. The period-over-period data reveals a troubling trend: revenue growth is anemic or negative for many, with net losses widening dramatically (MSP Recovery's loss doubled to $457.8M, Eagle Materials' earnings fell 9% despite record revenue). A wave of dilutive equity offerings (GeoVax, Rapid Micro, Sunshine Biopharma) and distressed debt exchanges (Jaguar Health, InMed) suggests a 'cash-for-equity' cycle is accelerating among micro-cap and clinical-stage biotechs. The most actionable insight is the stark contrast between well-capitalized firms using favorable debt markets to lock in low rates and distressed entities burning through their last options, creating a clear 'haves vs. have-nots' dynamic in the current credit environment.

40 high priority 40 total filings
· daily

US Executive Officer Management Changes SEC — May 19, 2026

This batch of 48 filings reveals a significant wave of leadership transitions across US equities, with notable CEO and CFO appointments at Rogers Corporation, Amerant Bancorp, and A. O. Smith, alongside the unexpected death of TOMI Environmental Solutions' CFO. A key theme is the high level of shareholder dissent on executive compensation, with Skyworks Solutions failing its say-on-pay vote (50.1% against) and several other companies (NOVAGOLD, Permian Resources, ACCO Brands) seeing over 20% opposition. Insider activity is limited to compensation-driven grants, but the lack of open-market purchases suggests caution. Forward-looking catalysts include Immunic's Phase 3 ENSURE trial readout by end of 2026 and Vistagen's new CMO appointment. Capital allocation trends show a focus on equity plan expansions (e.g., Roper Technologies adding 14.15M shares) rather than buybacks or dividends, signaling a bias toward employee retention. The most material event is the Skyworks say-on-pay failure, which could trigger board-level compensation reviews and potential activist interest.

48 high priority 48 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 19, 2026

The 48 filings reveal a heavy focus on annual meeting outcomes and board composition changes, with several high-profile director appointments and executive transitions. Notable trends include significant shareholder dissent on executive compensation and equity plan amendments at multiple companies (e.g., ACCO Brands, Skyworks Solutions, NOVAGOLD), indicating growing investor scrutiny. Several companies appointed new CFOs or CEOs (e.g., A. O. Smith, Rogers Corp, Amerant Bancorp), signaling strategic leadership shifts. The unexpected death of TOMI Environmental's CFO and the resignation of Upstart's board member Jeff Huber highlight succession risks. Overall, the period shows active governance changes with mixed shareholder sentiment, presenting both opportunities and risks for investors.

48 high priority 48 total filings
· daily

US Merger & Acquisition SEC Filings — May 19, 2026

The May 19, 2026, US M&A filing stream reveals a market bifurcated between high-conviction, well-capitalized take-privates and a flurry of SPAC deadline extensions signaling execution risk. The most material event is the $3.1B take-private of Mister Car Wash by Leonard Green & Partners, a definitive bullish signal for the sector that validates asset values. Conversely, the SPAC landscape shows systemic strain: three separate SPACs (Plum, Bayview, EagleRock) disclosed deadline extensions, with Bayview's fourth amendment pushing its closing date over 2.5 years from the original agreement, indicating severe deal fatigue. A major capital markets event was EagleRock Land's $286.6M IPO, a rare positive signal for the Permian Basin asset class. Insider activity was notably absent across the stream, with only one director resignation (Valuence Merger Corp.) that was non-disputative, providing no conviction signals. Forward-looking data points to a catalyst-rich June, with Exascale Labs' COMPUTEX Taipei exhibition and Eton's IMPAVIDO launch in September creating specific alpha opportunities. The aggregate trend shows capital rotating away from SPAC structures toward direct listings and take-privates, with the Mister Car Wash deal demonstrating the premium available for quality assets in a rate-stabilizing environment.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 19, 2026

Overnight filings reveal a market bifurcated between robust operational execution in infrastructure and energy transition versus acute distress in small-cap and commodity-exposed names. Home Depot's mixed quarter, with top-line growth but margin compression, sets a cautious tone for consumer spending, while Eagle Materials' record revenue but declining earnings highlights the 'growth without profit' theme in materials. The most significant corporate actions are the $2.2B acquisition of LiveRamp by Publicis and the $1.35B de-SPAC for Einride, signaling strong M&A appetite in data and green tech. However, a cluster of distressed signals—including Novelis's $84M loss from plant fires, TechPrecision's liquidity crunch, and Natural Alternatives' near-zero gross margin—demand immediate risk review. Insider activity is muted, but the conversion of GitLab's chair from supervoting to common stock is a notable governance event. The forward-looking calendar is packed with catalysts, including Thermon's merger vote, Immunic's Phase 3 readout, and multiple SPAC deadlines, offering both event-driven and turnaround opportunities.

22 high priority 28 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — May 18, 2026

The single contract analyzed, a $605M firm-fixed-price delivery order from DHS/CBP to Fisher Sand & Gravel for border wall construction in San Diego, represents a purely civilian infrastructure award with no defense exposure. The aggregate obligation of $605M is concentrated in a single private entity, limiting direct public equity impact but signaling sustained government investment in border security infrastructure. The highest-conviction signal is neutral, given the private recipient and high cost-overrun risk under a firm-fixed-price structure. Key risks include potential political shifts affecting border wall appropriations and execution risk for the contractor, which may indirectly affect publicly traded subcontractors or material suppliers.

1 total filings
· daily

DHS Homeland Security Contracts — May 18, 2026

This digest covers a single $605 million DHS/CBP contract awarded to privately held Fisher Sand & Gravel for border wall construction in San Diego (2026-2028). The award is entirely civilian (DHS), with no defense-related exposure, and carries a neutral signal strength of 5/10. The highest-conviction signal is the sustained government investment in border infrastructure, but the private nature of the recipient limits direct public equity impact. Key risks include execution risk under a firm-fixed-price structure and potential political volatility around border wall appropriations. Investors should watch for any publicly traded subcontractors or material suppliers that may benefit indirectly.

1 total filings
· daily

New Federal Contractors — May 18, 2026

The single contract analyzed, a $605M firm-fixed-price delivery order from DHS/CBP to private firm Fisher Sand & Gravel for border wall construction in San Diego, represents the entirety of the period's activity. This is a purely civilian award with no defense-related content, signaling sustained government investment in border infrastructure. The neutral signal strength (5/10) and lack of public equity exposure limit direct investment implications, but the contract's size and fixed-price structure create high execution risk for the private contractor. Key risks include political shifts in border policy and potential cost overruns, while opportunities lie in monitoring subcontractor disclosures for indirect public equity exposure.

1 total filings
· daily

Significant Contract Modifications ($10M+) — May 18, 2026

The two contracts analyzed represent $605.6 million in total obligations, both from civilian agencies (DHS and HHS), with zero defense-related awards. The dominant theme is a massive $605 million border wall construction contract awarded to private firm Fisher Sand & Gravel by DHS/CBP, signaling sustained government investment in border infrastructure despite political risks. The second contract, a $542,604 sterile water supply deal with Pfizer, is immaterial to the company's revenue. The highest-conviction signal is the border wall award's potential to benefit publicly traded subcontractors or material suppliers, though direct public equity exposure is absent. Key risks include execution risk under a fixed-price contract and political vulnerability of border wall funding to policy shifts.

2 total filings
· daily

Contract Option Exercises — May 18, 2026

The two contracts awarded on May 15, 2026, total $605.6 million in obligations, with zero defense-related awards — both are civilian agency contracts (DHS and HHS), highlighting a bifurcated government spending pattern. The dominant signal is a $605 million DHS/CBP border wall construction award to private firm Fisher Sand & Gravel, which, while not directly investable, signals sustained infrastructure spending that could benefit publicly traded subcontractors or material suppliers. The second award, a $542,604 HHS/ASPR sterile water contract to Pfizer, is immaterial to the company's $60B+ revenue base. The highest-conviction signal is the border wall contract's full competition after exclusion of sources, which introduces execution and political risk. Key watch items include potential subcontractor disclosures from Fisher Sand & Gravel and DHS budget appropriations for border security.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — May 18, 2026

The single mega-contract in this period is a $605M firm-fixed-price delivery order from DHS/CBP to privately held Fisher Sand & Gravel for border wall construction in San Diego. This is a purely civilian award with no defense exposure, signaling sustained government investment in border infrastructure under a full-and-open competition structure. The neutral signal strength (5/10) and lack of public equity direct exposure limit immediate investment implications, but the contract's size and fixed-price risk profile warrant monitoring for subcontractor or material supplier disclosures. Key risks include execution cost overruns on the fixed-price contract and potential budget or policy shifts affecting border wall appropriations.

1 total filings
· daily

High-Value Federal Grants ($5M+) — May 18, 2026

The single high-value grant analyzed for May 18, 2026, is a $605M firm-fixed-price delivery order from the Department of Homeland Security (DHS/CBP) to privately held Fisher Sand & Gravel for border wall construction in San Diego. This is a civilian contract with no direct defense exposure, and the neutral signal strength (5/10) reflects the lack of publicly traded prime exposure. The award underscores sustained government investment in border infrastructure, but execution risk is high given the fixed-price nature and political sensitivity. Key watch items include potential subcontractor disclosures and DHS budget appropriations for border security.

1 total filings
· daily

General Federal Contracts — May 18, 2026

This single-contract digest reveals a $605M civilian award from the Department of Homeland Security (DHS) to Fisher Sand & Gravel for border wall construction in San Diego, representing 100% of the period's total obligation. The contract is entirely civilian (0% defense-related) and carries a neutral signal strength of 5/10, reflecting the lack of direct public equity exposure due to the recipient's private status. The highest-conviction signal is the sustained government investment in border infrastructure, which may indirectly benefit publicly traded material suppliers or subcontractors. Key risks include execution risk from the firm-fixed-price structure and potential political volatility around border wall funding, particularly under a continuing resolution scenario.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 18, 2026

The 17 filings reveal a mixed landscape within the S&P 500 Technology sector and broader market. Key themes include significant insider buying at Genco Shipping, a large jury verdict against Acadia Healthcare, and a forward stock split for the abrdn Palladium ETF. Period-over-period trends show Genco's dramatic turnaround to profitability, while Madison Technologies remains revenue-less with worsening cash burn. Insider activity is sparse but notable at Genco, where management is actively opposing a tender offer. Capital allocation varies, with Genco increasing dividends and Cottonwood raising preferred equity. Forward-looking data highlights upcoming catalysts such as ImmunityBio's FDA engagement for BCG approval and RideNow's potential credit facility expansion. Overall, the digest points to selective opportunities in shipping and biotech, while caution is warranted for cash-burning microcaps and litigation risks.

6 high priority 11 medium 17 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 18, 2026

The 18 filings reveal a bifurcated landscape: while Genco Shipping & Trading and CoStar Group show strong operational turnarounds and proactive capital allocation, several biotech and cash-burning companies (Estrella Immunopharma, Madison Technologies) face liquidity pressures. Period-over-period comparisons highlight Genco's net income swing of +$21.2M YoY and CoStar's $1.5B buyback authorization, contrasting with Estrella's 28.5% G&A surge and Madison's zero revenue. Insider activity is limited but notable: Genco's CEO actively defends against a tender offer, while Acadia Healthcare faces a $105M adverse verdict. Forward-looking catalysts include MetaVia's ADA abstracts and ImmunityBio's BCG approval path. Sector themes center on capital discipline (shipping, real estate) versus speculative biotech spending, with a cautious tech hedge evidenced by Arkadios Wealth Advisors' large QQQ put positions.

5 high priority 13 medium 18 total filings